Keywords: antiplatelet/thrombolytic, combination, way, forward, mi, therapy, centocor/eli
Antiplatelet/thrombolytic combination: way forward for MI therapy?
Article | 01 September 1999
Centocor/Eli Lilly's blockbuster platelet glycoprotein IIb/IIIaantagonist ReoPro (abciximab) in combination with a low-dose of Centocor's own thrombolytic Retavase ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
